I. MODIFIED AGREEMENTS | |||
Company* |
Company* |
Change from original |
Terms/Details (Date) |
| | |||
Curis Inc. |
Genentech |
They amended June 2003 deal to extend Genentech's funding of the development collaboration in cancer |
Genentech is providing $2M to extend the Hedgehog-inhibition program, which was set to expire in June 2005, another six months, with a six-month option (4/14) |
Lexicon |
Deltagen Inc. (PK:DGENQ) |
They settled Lexicon's claim in Deltagen's bankruptcy proceedings and agreed on Deltagen's assumption of a sublicense deal from Lexicon |
Lexicon received $4M in the settlement and could get up to $6M more from Deltagen's licensing revenues from existing lines of knockout mice; Lexicon also is entitled to royalty payments (3/31) |
Transgenomic |
Geron Corp. (GERN) |
Transgenomic will provide additional modified nucleic acid-building block compounds to Geron |
The deal is an addendum to an existing master supply agreement between the companies; terms were not disclosed (4/20) |
II. TERMINATED AGREEMENTS | |||
Inex |
Enzon Pharmaceuticals Inc. (ENZN) |
Enzon is ending deal to develop Inex's cancer product Marqibo |
The product, vincristine sulfate liposomes injection, received a not- approvable letter from the FDA in January calling for more trials; Inex is due $5M under the deal (3/17) |
| | |||
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
NYSE = New York Stock Exchange; PK = Pink Sheets. | |||
